Related Experiment Video
Updated: May 10, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the
Raffaella Di Napoli1,2,3, Christophe Richez4,5, Cristina Scavone6,7,8
1Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology "L. Donatelli", University of Campania "Luigi Vanvitelli", Via Costantinopoli 16, 80138, Naples, Italy. raffaella.dinapoli@unicampania.it.
No abstract available in PubMed .
More Related Videos
Related Concept Videos
The JAK-STAT Signaling Pathway
Cardiovascular Drugs: Classification based on Therapeutic Indications
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Heart Failure Drugs: β-Blockers

